Can you buy zopiclone in the United States?

Product Name:	Zopiclone
Dosage:	7.5 mg
Price:	$75.00
Where To Buy Online	Online Pharmacy

Insomnia treatment made simple

Complete a short online consultation and, if appropriate, your prescription will be approved online. Your medication is then delivered direct to your door in discreet packaging within 2-3 business days.

Start my consultation

Zopiclone is not FDA-approved in the United States. The related medicine available as an FDA-approved prescription treatment is eszopiclone, sold as Lunesta and as a generic. An online listing for zopiclone does not change its U.S. approval status, and Lunesta is not simply a different brand of zopiclone. [1]

In countries where it is licensed, zopiclone is used for short-term insomnia. Understanding the active ingredient, the intended market and the prescribing information comes before comparing tablet strengths or advertised prices. These distinctions also determine which treatment instructions apply.

Can you buy zopiclone online in the U.S.?

Zopiclone is not an FDA-approved option for ordinary U.S. prescribing and pharmacy dispensing. Its availability in another country should not be confused with approval in the United States. A website can display a product name, a price in dollars and a prescription statement without establishing U.S. approval. The relevant distinction is the medicine's regulatory status, not the currency used to advertise it. [1]

Eszopiclone is the related U.S.-approved medicine. A prescription for it identifies eszopiclone and its prescribed strength; a zopiclone product is not a generic substitute for that prescription. A brand name, generic name and related molecule describe different relationships, which are easy to overlook when comparing short product listings.

Prescription status, brand names and generic medicines

"Prescription-only" and "FDA-approved" answer different questions. The first describes how a medicine may be supplied in a particular jurisdiction. The second concerns approval of a product in the United States. A statement that a seller requires a prescription does not, by itself, answer the approval question.

A generic medicine should also be distinguished from a related medicine. Generic eszopiclone contains eszopiclone. Lunesta contains eszopiclone. Zopiclone contains a mixture of enantiomers and is a separate active ingredient. Calling all three names interchangeable would obscure the very information a patient needs to identify the prescribed treatment. [2]

For a reader who encountered zopiclone through treatment abroad, the useful starting point is the name and strength on the original prescription or packaging. That record describes what was previously used; it does not establish that the same product is approved in a new country. Past experience and present prescribing options should be recorded separately.

U.S. availability: eszopiclone (Lunesta)

Zopiclone contains two mirror-image molecular forms, called enantiomers. Eszopiclone is the S-enantiomer. This explains the relationship more accurately than describing Lunesta as a new brand of zopiclone or assuming that it is simply a stronger version.

U.S. eszopiclone tablets contain 1 mg, 2 mg or 3 mg. A zopiclone strength of 7.5 mg cannot be carried across to an eszopiclone prescription. Comparing the numbers on the packaging without identifying the active ingredient would compare different treatments as though their dosing scales were identical. [2]

The distinction also affects practical instructions. The U.S. Lunesta label cautions against taking it with or immediately after a meal; a heavy, high-fat meal can delay its effect on sleep onset. By contrast, the UK Zimovane information states that food does not change zopiclone absorption. Instructions copied from one medicine to the other can therefore be wrong even when the names look familiar. [2] [3]

For a treatment-focused overview, read our guide to zopiclone effects, clinical evidence and safety.

What zopiclone does, and what improvement means

Zopiclone acts at the GABA-A receptor complex, enhancing an inhibitory signaling system in the brain. Its chemical structure differs from benzodiazepines, but that difference does not remove the potential for sedation, impaired coordination or dependence. "Non-benzodiazepine" describes its drug group; it is not a safety guarantee. [3]

Sleep improvement is not a single measurement. A person may fall asleep sooner but still wake repeatedly, or spend longer asleep but feel less alert the following morning. Those outcomes should not be collapsed into an unqualified claim that a treatment produces "better sleep." A useful assessment separates the nighttime benefit from daytime functioning.

Zopiclone and eszopiclone compared

Medicine identity and market-specific prescribing information
Question	Zopiclone	Eszopiclone / Lunesta
What is the active ingredient?	A mixture of R- and S-enantiomers	The S-enantiomer
Is it FDA-approved?	No	Yes, for insomnia
Which product information is discussed here?	UK Zimovane prescribing information	U.S. Lunesta prescribing information
Can the same milligram dose be substituted?	No direct substitution is established here	Requires its own prescription and dosing instructions

The table compares identities and regulatory information, not which medicine is best for a particular person. A difference in approval status is not a head-to-head efficacy result. Conversely, a shared molecular component is not evidence that the products can be substituted at the same dose. [1] [2] [3]

What comparative research can tell us

A systematic review published in 2004 assessed 24 trials involving 3,909 participants, comparing Z-drugs with benzodiazepines or with one another. The investigators found few clear, consistent differences. Reporting limitations meant that only some outcomes could be pooled. [4]

That result does not establish that every sleeping medicine is equivalent. It means the included studies did not support a simple, dependable ranking across the outcomes examined. The review is also old: it should not be presented as a current head-to-head comparison covering every treatment available today.

A separate randomized trial published in JAMA in 2006 compared cognitive behavioral therapy, zopiclone and placebo in 46 adults with chronic primary insomnia. Their mean age was 60.8 years. Treatment lasted six weeks, with follow-up of the active groups at six months. CBT performed better than zopiclone on three of four measured outcomes. [5]

At six months, sleep efficiency in the CBT group had risen from 81.4% to 90.1%; the zopiclone group changed from 82.3% to 81.9%. Sleep efficiency is the proportion of time in bed actually spent asleep. Total sleep time was similar across groups.

This was a small, single-center study of older adults with a particular form of chronic insomnia. It cannot establish that zopiclone never helps, or predict how a younger individual with a brief episode of insomnia will respond. Its relevance is the distinction between short-term medication use and durable management of persistent insomnia.

Onset, tablet strengths and treatment length

The NHS gives an approximate onset of 30-60 minutes. This is a population-level estimate rather than a countdown: not falling asleep at a particular minute is not an instruction to repeat the dose. NHS instructions say not to take more than one dose during the same night or double a missed dose. [6]

A tablet strength and a treatment plan answer different questions. The strength identifies the amount of active ingredient in a tablet. It does not identify the appropriate dose for every adult, establish a course length or indicate when another dose is appropriate. Likewise, the number of tablets in a package does not determine how long treatment should continue.

UK Zimovane labeling limits treatment to a short course, generally no longer than four weeks including tapering. It also provides lower starting doses for certain groups, including older adults. These are prescribing details for a licensed UK product, not evidence of U.S. approval or a self-treatment plan. [3]

Onset and elimination are different concepts. The first describes when an effect becomes noticeable; the second concerns how the body clears the medicine. A quick onset does not establish that the medicine will have cleared by the following morning. For the same reason, a claimed "duration of sleep" should not be treated as a guarantee about driving ability.

Dependence, tolerance and stopping treatment

These terms describe different problems. Tolerance means that the same dose may produce less effect over time. Physical dependence involves adaptation to repeated exposure, with symptoms possible when treatment is reduced or stopped. Addiction includes difficulty controlling use despite harm. Physical dependence does not, by itself, mean that someone has an addiction.

In January 2026, the MHRA announced stronger warnings about addiction, dependence, withdrawal and tolerance for Z-drugs and related medicine groups. Its review emphasized that these problems can arise even when medicines are taken as directed. [7]

Consequently, the end of treatment belongs in the initial discussion. After regular use, suddenly stopping or making a large reduction can trigger withdrawal. The stopping plan should reflect the actual dose, duration and symptoms rather than a universal schedule copied from an article.

A return of poor sleep can be difficult to interpret. It may reflect the original insomnia, rebound symptoms after stopping, or a combination. Automatically resuming or increasing treatment without reviewing the sequence can obscure what happened. The useful information is the timing of symptoms relative to dose changes, together with other changes in health or medication.

Side effects: common symptoms and urgent problems

A metallic or bitter taste, dry mouth and next-day tiredness are recognized effects. Dizziness, reduced concentration or poor balance also matter because the consequence may be a fall or impaired driving rather than simply an unpleasant sensation. NHS advice is to avoid driving, cycling and machinery for at least 12 hours after zopiclone, and longer while impairment persists. [6]

Complex sleep behaviors are a different concern. Sleepwalking, preparing food or driving while not fully awake may occur without a clear memory afterward. U.S. FDA warnings for eszopiclone, zolpidem and zaleplon describe serious injuries and deaths associated with these behaviors. They can occur after an initial dose as well as during continued use. [8]

These episodes should not be dismissed as an ordinary vivid dream. FDA guidance is to stop the implicated medicine and contact the prescriber immediately. Severe breathing difficulty, collapse or inability to wake someone require emergency assistance.

The regulatory warning for U.S. Z-drugs and the UK instructions for zopiclone are separate sources. Both are relevant to understanding this drug group, but a warning on one product should not be presented as though it were the complete prescribing information for another.

Other medicines, alcohol and individual health conditions

A medication review needs exact names, not broad categories such as "a painkiller" or "an allergy tablet." These descriptions can refer to products with very different ingredients. The same applies to nighttime combination remedies: a familiar brand name does not reveal every active component.

The NHS lists interactions with other sleep or anxiety medicines, opioid painkillers, sedating antihistamines and some antidepressants, antibiotics and antifungals. Alcohol can intensify the effects and cause breathing problems or make waking difficult. [6]

The UK Zimovane product information lists severe sleep apnea, respiratory failure, severe liver impairment, myasthenia gravis and previous complex sleep behavior with zopiclone among its contraindications. [3] This is not an exhaustive eligibility checklist; identifying one absent condition does not establish that treatment is suitable.

Pregnancy and breastfeeding need a separate assessment. NHS information says zopiclone is not usually used during pregnancy, although exceptional short-term use may be considered. It can enter breast milk. Sedating medication is also a reason not to share a bed with a baby. These circumstances should not be reduced to a blanket assurance that a low dose is safe. [6]

Where medication fits in longer-term insomnia care

For persistent insomnia, the central question is what will sustain improvement after a medicine is withdrawn. The NHLBI describes CBT-I as the usual first treatment option for long-term insomnia. It typically involves a structured six- to eight-week plan, delivered in person, by telephone or online. [9]

CBT-I is more specific than a list of sleep-hygiene tips. Stimulus control works on the association between bed and wakefulness. Sleep restriction adjusts time in bed to consolidate sleep. Cognitive work addresses worries and expectations that perpetuate sleeplessness. Relaxation and sleep education can be included.

This distinction matters when someone says they have "already tried everything" after changing pillows, avoiding coffee or keeping the room dark. Those changes may help, but they do not demonstrate that a structured CBT-I program has been tried and failed. Medication and behavioral treatment should also be judged over appropriate timeframes: benefit on a particular night and benefit months later are different outcomes.

A clear account of symptoms makes those comparisons more useful. Record whether the main problem is falling asleep, waking repeatedly, waking too early or feeling unrefreshed, and whether the pattern changed during treatment. This gives a more informative picture than a single statement that a tablet is "strong" or "weak."

Frequently asked questions

Is Lunesta simply purified zopiclone?

Eszopiclone is one enantiomer of zopiclone. "Purified" can misleadingly suggest that racemic zopiclone is contaminated, while "more modern" implies a clinical advantage without specifying an outcome. The useful distinction is the active ingredient, its approved uses and its own prescribing instructions. [2]

Does FDA approval mean eszopiclone is appropriate for everyone?

No. The U.S. label contains restrictions and warnings, including a boxed warning for complex sleep behaviors. Approval establishes an authorized treatment with defined labeling; it does not remove individual contraindications, interactions or adverse effects. [2]

Does a bitter taste mean the dose is wrong?

A bitter or metallic taste is a recognized side effect. It cannot, on its own, establish whether the dose is correct, whether the treatment is working or whether a tablet is genuine. Those are separate questions. [6]

Why can I feel sleepy in the morning after sleeping all night?

Sleeping through the night does not prove that a medicine's effects have ended. U.S. Lunesta labeling warns about next-day impairment, which can occur without a person recognizing it. A full sleep opportunity is important but is not a guarantee of unimpaired performance. [2]

Why advertised prices are difficult to compare

A price without a specified package is incomplete. A meaningful comparison identifies the active ingredient, strength, number of tablets, brand or generic status, country and what the charge includes. A medication price and a consultation fee are separate costs; combining or omitting them can make two offers appear equivalent when they are not.

The same problem arises when a page switches between zopiclone and eszopiclone while discussing cost. Prices for products containing different active ingredients should not be combined into one range. Likewise, a cash price abroad is not evidence of a U.S. insurance benefit or of availability through a U.S. pharmacy.

No zopiclone sales price or U.S. purchase offer is provided here. The purpose of this comparison is to explain why an unspecified headline price cannot establish what treatment someone would receive, whether it matches a prescription or which country's product rules apply.